Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Olmez, Omer Fatih | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | Oksuzoglu, Berna | |
dc.contributor.author | Kaplan, Muhammet Ali | |
dc.contributor.author | Karadurmus, Nuri | |
dc.contributor.author | Cubukcu, Erdem | |
dc.date.accessioned | 2024-04-24T17:50:00Z | |
dc.date.available | 2024-04-24T17:50:00Z | |
dc.date.issued | 2022 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description | Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | Amer Soc Clin Oncol | en_US |
dc.description.sponsorship | Roche Pharmaceuticals | en_US |
dc.description.sponsorship | Roche Pharmaceuticals. | en_US |
dc.identifier.issn | 0732-183X | |
dc.identifier.issn | 1527-7755 | |
dc.identifier.issue | 16 | en_US |
dc.identifier.uri | https://hdl.handle.net/11468/23147 | |
dc.identifier.volume | 40 | en_US |
dc.identifier.wos | WOS:000863680302513 | |
dc.identifier.wosquality | Q1 | |
dc.indekslendigikaynak | Web of Science | |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.relation.ispartof | Journal of Clinical Oncology | |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keyword] | en_US |
dc.title | Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). | en_US |
dc.title | Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). | |
dc.type | Conference Object | en_US |